NEW YORK — Aalto Bio Reagents said today that it has signed a Japanese distribution deal for its products with Tokyo-based Veritas.
Specific terms of the deal were not disclosed.
Dublin, Ireland-based Aalto is a provider of raw materials for in vitro diagnostics including purified human proteins, monoclonal and polyclonal antibodies, viral antigens, and disease state plasma.
"We are excited to be collaborating with such an esteemed partner in Japan, allowing us to target a fifth new market this year identified under our strategic growth plan," Aalto CEO Philip Noone said in a statement. "We will continue to focus on the expansion of our infectious disease and clinical chemistry products throughout 2019 and 2020."